Showing results (181-190 of 366) with videos related to
Sort By:
Pageof 37
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical TrialEdward B Garon, Alexander I Spira, Sarah B Goldberg, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 25, 2023
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 TrialMartin Reck, Fabrice Barlesi, James Chih-Hsin Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung CancerMartin Reck, Alexander Luft, Aleksandra Szczesna, et al.Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.Lancet (London, England)|September 23, 2021
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.Nature Genetics|September 12, 2024
Five latent factors underlie response to immunotherapyJoseph Usset, Axel Rosendahl Huber, Maria A Andrianova, et al.Breathe (Sheffield, England)|February 18, 2017
Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncologyFernando Gamarra, Julie-Lyn Noël, Alessandro Brunelli, et al.Molecular Oncology|December 20, 2020
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancerJoan Frigola, Alejandro Navarro, Caterina Carbonell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2018
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung CancerYi-Long Wu, Li Zhang, Dong-Wan Kim, et al.European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.Pageof 37